Effects of tranexamic acid on the activity of glutamate transporter EAAT3

Anesth Pain Med (Seoul). 2020 Jul 31;15(3):291-296. doi: 10.17085/apm.20004.

Abstract

Background: Tranexamic acid (TXA) is the most widely used hemostatic agent in surgical patients. However, when used in a high dose, it could cause a seizure in the postoperative period. The exact effector mechanism behind the seizure triggering remains unknown. Therefore, the authors investigated the effects of TXA on the activity of glutamate transporter type 3 (excitatory amino acid transporter 3; EAAT3), which is the main neuronal glutamate transporter type.

Methods: EAAT3 was expressed in Xenopus laevis oocytes through mRNA injection. Oocytes were incubated with diluted tranexamic acid for 72 h. Two-electrode voltage clamping was used to measure membrane currents before, during, and after applying 30 µM L-glutamate. Responses were quantified by integrating the current traces and reported in microcoulombs (µC). Results were presented as mean ± SEM.

Results: TXA (30 to 1,000 µM) significantly decreased EAAT3 activity. Our kinetic study showed that Vmax was significantly decreased in the TXA group compared with the control group (1.1 ± 0.1 vs. 1.4 ± 0.1 µC, n = 18-23, P = 0.043), but the Km did not significantly change (12.7 ± 3.9 µM for TXA vs. 12.8 ± 3.8 for control, n = 18-23, P = 0.986).

Conclusions: Our results suggest that TXA attenuates EAAT3 activity, which may explain its proconvulsant effect.

Keywords: Electrophysiology; Excitatory amino acid transporter 3; Glutamate plasma membrane transport proteins; Tranexamic acid; Xenopus laevis.